Longevity & Metabolic Biomarker Ranges

This is an educational reference of biomarker ranges with the guideline source for each. It is not a set of personal targets. A “standard” range is the lab or diagnostic-guideline range (ADA, NCEP, KDIGO); an “optimal” range is a tighter target that is sometimes guideline-backed and sometimes only a longevity-community convention. We label which is which so you can tell evidence from aspiration. Only a licensed clinician can interpret your results.

Longevity medicine is built on a simple idea: measure the biological processes that drive aging, then act on them before they become illness. That framework comes from the established hallmarks of aging, the cellular and metabolic processes (metabolic regulation, inflammation, hormonal balance, cellular repair) that underlie how we age. Biomarkers are how those processes show up in a blood draw.

A single lab value rarely tells the whole story. What matters is the pattern across marker classes, metabolism, inflammation, lipids, hormones, and cellular function, and how that pattern moves over time. This is why longevity medicine tracks markers as a trajectory rather than a pass-or-fail cutoff, and why every result is interpreted by a physician in the context of your history.

The ranges below separate two things that are often blurred together: the conventional guideline range used to diagnose disease, and the tighter “optimal” target some longevity practitioners pursue. Where the optimal target is guideline-backed, we say so. Where it is only a community convention, we say that too.

Metabolic markers show how well the body handles glucose and insulin. HbA1c reflects roughly the prior three months of blood glucose, while fasting glucose and fasting insulin capture a single point in time. Fasting insulin and the calculated HOMA-IR index can flag insulin resistance earlier than glucose alone, because insulin often rises before glucose does.

Insulin resistance is central to how metabolism ages. It is the loss of responsiveness to insulin that drives the slide from normal glucose tolerance toward prediabetes and type 2 diabetes. The mechanisms of insulin action and resistance are documented in detail in the physiology literature. Tracking metabolic markers over time is how a clinician watches that trajectory.

Source: Petersen MC, Shulman GI. Physiol Rev. 2018;98(4):2133-2223. (Mechanisms of insulin action and insulin resistance.) Mechanistic background only; not a treatment claim.

High-sensitivity CRP (hs-CRP) is the most common marker of low-grade vascular inflammation. The CDC/AHA tiers (low under 1 mg/L, average 1–3 mg/L, high over 3 mg/L) are cardiovascular-risk strata, not a diagnostic cutoff for any one disease. The 2018 ACC/AHA guidance treats 2.0 mg/L or higher as a statin “risk-enhancer.”

Chronic, low-grade inflammation is one of the recognized hallmarks of aging. The research literature describes this as inflammaging, a persistent, sterile inflammatory state that accumulates with age and is implicated in many age-related conditions. hs-CRP is one window onto that process, but it is nonspecific: it rises with acute illness, injury, or infection, so an isolated high value should be repeated before it means anything.

Source: Ajoolabady A, et al. Ageing Res Rev. 2024;101:102540. (Immunosenescence and inflammaging.) Mechanistic background only; not a treatment claim.

Lipids are where conventional and “optimal” ranges diverge most clearly. LDL-C measures the cholesterol carried in LDL particles. ApoB counts the particles themselves. Every atherogenic particle (LDL, VLDL, Lp(a)) carries one ApoB molecule, so when LDL-C and ApoB disagree, cardiovascular risk tends to track ApoB. This is why ApoB is increasingly preferred for risk assessment.

Lp(a) is different: it is largely genetically determined, stays fairly stable through life, and is not meaningfully lowered by diet or standard lipid therapy. Knowing your Lp(a) once helps stratify lifetime cardiovascular risk. Units matter for Lp(a), because nmol/L (particle count) and mg/dL (mass) convert only approximately, so the reporting unit should always be noted when comparing results.

The “optimal” targets in this class split by evidence: the 2019 ESC/EAS ApoB target of under 65 mg/dL for high-risk patients is a guideline, while a general “ApoB under 80” is a longevity-community convention without screening-guideline backing.

Hormonal balance is one of the recognized hallmarks of aging, and hormone panels are ordered when they are relevant to your symptoms and goals. Sex hormones (testosterone, estradiol), thyroid markers, and related measures can change with age, and tracking them helps a clinician see whether a symptom pattern has a hormonal explanation.

Hormone interpretation is highly individual. A value that is “normal” on paper can still be meaningful in context, and a value outside the lab range is not always a problem. This is why we do not list fixed “optimal” hormone numbers here: hormone results are read against your history, age, sex, and symptoms by a physician, never against a generic target.

Cellular markers look at the machinery of aging itself rather than its risk factors. NAD+ is a cellular coenzyme central to energy metabolism and the repair pathways whose decline is linked to aging. The research literature documents how NAD+ availability falls with age and how this connects to metabolic and neurodegenerative conditions.

There is currently no single agreed “optimal” blood NAD+ level, and it remains an active area of study, so we treat NAD+ as a mechanistic marker rather than a number to chase. The same is true of biological-age estimates derived from DNA methylation (epigenetic clocks): they are promising research tools, but they are emerging indicators, not settled measurements with universal cutoffs.

Source: Verdin E. Science. 2015;350(6265):1208-1213. (NAD+ in aging, metabolism, and neurodegeneration.) Mechanistic background only; not a treatment claim.

At LiveNow Longevity, biomarkers are read by Dr. Charles Kamen, MD, a board-certified neurologist, in the context of your whole history rather than against a generic checklist. The reference above is the framework; your actual plan is built from your own labs, your symptoms, and your goals.

Care begins with an $88 evaluation. Baseline labs are ordered based on your history and goals, and any follow-up protocol is tied to a specific finding in your results. We track the markers that matter for you over time so progress is measured against your own baseline, not a feeling. Nothing here is a treatment recommendation — every decision is made after medical evaluation.

This reference sits alongside our longevity medicine program. If you want your labs read by a physician rather than a reference table, start with the $88 evaluation.

• Petersen MC, Shulman GI. Physiol Rev. 2018;98(4):2133-2223. (Mechanisms of insulin action and insulin resistance).
• López-Otín C, et al. Cell. 2013;153(6):1194-1217. (The hallmarks of aging).
• Verdin E. Science. 2015;350(6265):1208-1213. (NAD+ in aging, metabolism, and neurodegeneration).
• Ajoolabady A, et al. Ageing Res Rev. 2024;101:102540. (Immunosenescence and inflammaging: mechanisms and role in disease).

Background mechanistic sources only — the hallmarks of aging, insulin resistance, inflammaging, and NAD+ biology. Not a treatment claim. Reference ranges are educational; your physician interprets your results in context.